MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2015.569 MCO-0-0-569 Articles β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma WANGZHENG 1 2 * SHENGYUAN-YUAN 2 * GAOXIAO-MEI 2 WANGCHAO-QUN 1 2 WANGXIANG-YU 1 2 LUXU 1 2 WEIJIN-WANG 2 ZHANGKAI-LI 2 DONGQIONG-ZHU 1 2 QINLUN-XIU 1 2 Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China Institute of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China Correspondence to: Professor Lun-Xiu Qin or Qiong-Zhu Dong, Department of Surgery, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai 200040, P.R. China, E-mail: qin_lx@yahoo.com, E-mail: qzhdong@fudan.edu.cn

Contributed equally

 07 2015 15 05 2015 3 4 936 940 08122014 15042015 Copyright © 2015, Spandidos Publications 2015

The β-catenin gene is frequently mutated in patients with hepatocellular carcinoma (HCC) and has long been thought to be one of the major oncogenes involved in the hepatocarcinogenesis. The prognostic role of β-catenin mutation in HCC remains unclear. To address this issue, a search for relevant studies was performed in the PubMed, Embase and Web of Science databases. The pooled effect was calculated from the available data to evaluate the correlation of β-catenin mutation with overall survival rate and tumor clinicopathological features in patients with HCC. The pooled odds ratio (OR) was calculated using the Mantel-Haenszel model for fixed effects. Three studies met the inclusion criteria. A total of 618 cases were included, and β-catenin mutation was identified in 104 of them. The meta-analysis revealed that the presence of β-catenin mutation (n=104), compared with the control group (n=514), was correlated with a longer overall survival rate [OR, 0.33; 95% confidence interval (CI), 0.21–0.53; P<0.00001] in patients with HCC. No significant heterogeneity was found among the eligible studies (I2=0%; P=0.72). β-catenin mutation was correlated with a relatively lower rate of hepatitis B virus infection (OR, 0.36; 95% CI, 0.21–0.61; P=0.0002), improved tumor differentiation (OR, 0.32; 95% CI, 0.19–0.56; P<0.0001) and a lower tumor-node-metastasis stage (I+II) (OR, 0.23; 95% CI, 0.14–0.38; P<0.00001). These findings suggest that β-catenin mutation may predict a favorable prognosis in patients with HCC.

 hepatocellular carcinoma β-catenin mutation prognosis clinicopathological parameters meta-analysis Introduction

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third most frequent cause of cancer-related fatality worldwide (1). It is estimated that 750,000 new cases occur globally per year, half of which are reported in China (2,3). Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is thought to be the most frequent etiology of HCC (4). Additionally, interaction of aflatoxin B1 (AFB) exposure with HBV infection is believed to increase the prevalence of HCC (5). Tobacco, alcohol and obesity are also co-morbidity risk factors for HCC (6,7). However, environmental contributing factors can only partially explain the pathogenesis of HCC.

Hepatocarcinogenesis is a complex multistep process involving numerous signaling pathways (8). The signaling pathways, linked to distinct categories, such as proliferation, apoptosis, metabolism, splicing, chromatin biology and cell cycle, play crucial roles in the development of HCC (9). The Wnt-β-catenin signaling pathway regulates various processes that are important for cancer progression, including tumor initiation, growth, survival, migration, differentiation and apoptosis (10). Hyperactivation of this signaling pathway, stimulated by upstream molecules, occurs in a third of all HCCs and represents the major oncogenic driver (11).

β-catenin, the central hub of the canonical Wnt signaling pathway, has several biological functions that are referred to as oncogenic activities (12). Over the past few decades, numerous studies have explored the genetic profiles associated with cancer predisposition, and a high frequency of β-catenin mutation in HCC has been reported (13–17). According to the latest findings from whole-genome research in HCC patients, the β-catenin gene is the most frequently mutated oncogene (18). Additionally, several studies have shown that crosstalk between mutant β-catenin and other oncogenes or tumor suppressor genes, such as H-ras and Met, was involved in tumorigenesis in the liver (19,20). In addition, it has been shown that a molecular subclass specific to β-catenin mutation in HCC was associated with certain clinical characteristics (21,22). These previous studies indicate the importance of β-catenin mutation in the initiation and progression of HCC. However, limited evidence has indicated an association between β-catenin mutation and the survival rate in HCC patients, and the prognostic significance of β-catenin mutation in HCC patients remains unclear.

In the present study, a meta-analysis was performed of the published studies to investigate the prognostic significance of β-catenin mutation in HCC cases. The results showed that β-catenin mutation is correlated with favorable prognosis in HCC patients.

 Materials and methods <sec> <title>Search strategy

Aa search of the PubMed, Embase and Web of Science databases was performed for the relevant studies published until September 1, 2014. The databases were searched using the following algorithm without language limits: (‘β-catenin’ OR ‘beta-catenin’ OR ‘CTNNB1’) and (‘prognosis’ or ‘prognostic’ or ‘survival’) and (‘HCC’ or ‘hepatocellular neoplasm’ or ‘liver cancer’ or ‘HCC’). All the references cited in the relevant studies were used to identify additional eligible studies. For further full-text review and data extraction, only studies in English were included.

 Inclusion and exclusion criteria

Studies were included in the present meta-analysis if they met the following inclusion criteria: i) Studies were written in the English language, ii) patients were diagnosed with HCC by pathological examination, iii) the samples used for the mutational analysis were obtained from surgical tumor tissue specimens, iv) β-catenin mutation was detected, and v) data were sufficient for the estimation of the hazard ratio (HR) or odds ratio (OR) and their respective 95% confidence intervals (CIs).

The following studies were excluded: i) Non-English publications; ii) reviews, letters, case reports and conference abstracts without original data; iii) duplications of previous studies and replicated samples; and iv) studies from which sufficient data could not be extracted.

 Data extraction and quality assessment

Two investigators (Z Wang and YY Sheng) screened the included studies and independently extracted the raw data from all the eligible studies. For each study, the following information was collected: First author name, publication date, number of patients, gender of patients, tumor-node-metastasis stage, tumor differentiation, research technique, definition of β-catenin mutation and overall survival. Study quality was assessed independently by two investigators (Z. Wang and Y.Y. Sheng) according to the Newcastle-Ottawa scale (23). Disagreements were settled by discussion among the authors.

 Statistical analysis

Outcomes of the eligible studies were analyzed in Review Manager Version 5.2. The statistical methods used were in accordance with the Cochrane Handbook for Systematic Review of Interventions (Version 5.1.0, updated March 2011).

The dichotomous variables were analyzed by estimating the OR and 95% CI. The statistical method used was the Mantel-Haenszel fixed-effects model. The I2 value was calculated to evaluate the heterogeneity of the study, and heterogeneity was considered present if the I2 statistic was ≥50%. All the P-values were found by a two-sided test and P<0.05 was considered to indicate a statistically significant difference. A funnel plot was used to evaluate the potential publication bias.

 Results <sec> <title>Description of studies

A flow diagram illustrating the search and selection criteria is provided in Fig. 1. The initial search strategy yielded 699 studies. On the basis of the titles and abstracts, 677 studies (including 88 reviews, 40 conference papers, 21 animal studies, 52 cell line studies and 476 studies that had no association with the present study) were excluded. Following screening of the full text, 4 studies were excluded that were unavailable, 1 was not written in English and 14 did not provide useful data. Three studies with a total number of 618 patients (104 with β-catenin mutations and 514 with wild-type β-catenin) were ultimately included in the analysis. Their characteristics are summarized in Table I. The studies in the meta-analysis were published between 2000 and 2011. Polymerase chain reaction (PCR) and DNA sequencing were used to detect β-catenin mutations. The association between β-catenin mutation and overall survival rate was investigated, and the end-point of follow-up was set at 5 years in all the studies.

 Quality assessment

Each of the 3 studies eligible for analysis was assessed according to the ‘Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses’ standard. The NOS has 8 items categorized in three dimensions: Selection, comparability and exposure. A study can be awarded a maximum of 1 star for each numbered item within the selection and exposure categories, and a maximum of 2 stars in the comparability category. In total, quality scores range from 0 to 9 stars, and a study with a score of ≥6 is defined as a high-quality study. On the basis of the NOS, all 3 studies included in the meta-analysis were of high quality (Table I).

 Impact of β-catenin mutation on the overall survival rate in HCC patients

Among the included studies, the β-catenin mutation rate ranged from 12.8–44.4%, and the mean incidence of β-catenin mutation was 16.6%. The majority of mutations occurred at the phosphorylation sites for GSK-3β binding in exon 3. The meta-analysis was conducted to assess the association between β-catenin mutation and the overall survival rate of HCC patients. The pooled OR was 0.33 (95% CI, 0.21–0.53; Z=4.58; P<0.00001) (Fig. 2A). The I2 test (I2=0%; P=0.72) showed no significant heterogeneity between the 3 included studies. This result indicated that β-catenin mutation was correlated with a favorable prognosis in patients with HCC.

 Correlation of β-catenin mutation with clinicopathological parameters

Two of the studies evaluated the correlation of β-catenin mutation with HBV infection. The pooled OR was 0.36 (95% CI, 0.21–0.61; Z=3.77; P=0.0002) (Fig. 2B) without heterogeneity (I2=0%; P=0.88). This result indicated that β-catenin mutation occurred more frequently in patients who were negative for HBV. Additionally, 2 studies assessed the correlation between β-catenin mutation and tumor differentiation. The pooled OR was 0.32 (95% CI, 0.19–0.56; Z=4.06; P<0.0001) (Fig. 2C), suggesting that β-catenin mutation was associated with well-differentiated tumors. The incidence of β-catenin mutation was significantly higher in stage I+II carcinomas compared to stage III+IV carcinomas (OR, 0.23; 95% CI, 0.14–0.38; Z=5.78; P<0.00001) (Fig. 2D). Thus, β-catenin mutation was correlated with a subset of well-differentiated, low-stage HCCs in HBV-negative patients.

 Publication bias

A funnel plot assessment was performed (Fig. 3), which indicated that no significant publication bias existed for the studies included in the meta-analysis.

 Discussion

The Wnt signaling pathway plays a crucial role in the pathogenesis of HCC, and β-catenin serves as the core component of this pathway (24). The association between β-catenin mutation and prognosis in HCC patients was first reported in 2000 (25). Since then, however, few studies have further explored this area (26,27). Therefore, it is necessary to analyze the existing data regarding β-catenin mutation in HCCs to draw a reasonable conclusion regarding its prognostic significance. The present systematic meta-analysis assessed comprehensive evidence regarding the prognostic significance of β-catenin mutation in HCC patients who received surgical treatment. The results suggest that the presence of β-catenin mutation predicts a favorable prognosis in HCC patients, which provides useful information for decision-making in the treatment of HCC.

β-catenin, a multifunctional cytoplasmic protein, is maintained at a low steady-state level in the absence of Wnt signaling. Alterations of the Wnt-β-catenin pathway are involved in the pathogenesis of HCC. β-catenin mutation, which is highly frequent in patients with HCC, can influence the proliferation, motility, apoptosis and senescence of cancer cells (28). It has been previously shown that β-catenin mutation was more frequent in small colorectal adenomas compared to larger adenomas and invasive carcinomas (29) and that it was associated with good clinical outcomes in ovarian carcinoma (30). These observations are consistent with the present finding that β-catenin mutation was significantly associated with a relatively good prognosis in HCC cases. Based on the findings of these previous studies, investigators have studied and identified possible mechanisms involved in this phenomenon. The studies by Sekine et al (31,32) demonstrated that a β-catenin loss-of-function mutation affected glutamine synthesis pathway activity in mice and, thus, delayed hepatocyte proliferation following partial hepatectomy. Additionally, Apte et al (33) reported that β-catenin mutation, cooperating with the hepatocyte growth factor-mediated signaling pathway, impaired liver growth and minimized the pathogenesis of HCC. In addition, Harada et al (34) found that β-catenin gain-of-function mutations did not induce hepatocarcinogenesis in a mice model. These results may partially account for the correlation of β-catenin mutation with a longer survival rate in HCC.

The present results also demonstrated that β-catenin mutation occurred more frequently in HBV-negative patients. This finding was supported by recent studies of whole-genome sequencing in HCC, confirming that the rate of β-catenin mutation was much higher in HCV-related HCC compared to HBV-related HCC (17,35,36). Additionally, the association between β-catenin mutation and clinicopathological features of HCC was analyzed and β-catenin mutation was associated with improved tumor differentiation and a lower tumor stage. The improved tumor differentiation and lower tumor stage may indicate a relatively lower primary tumor aggressiveness and a decreased probability of metastasis. This result is consistent with the present finding that β-catenin mutation predicts a favorable prognosis in HCC.

To avoid a potential influence of the studies with insufficient data on the reliability of this systematic review, only high-quality studies with large sample sizes (≥100) were included in the meta-analysis, as these factors offer a more reliable analysis. In addition, all of the samples for the β-catenin mutation analysis were obtained from surgical tumor tissue specimens and the end-point of follow-up was set at 5 years in all the eligible studies. Furthermore, the combined analysis of the studies yielded similar results to those of the meta-analysis of all the eligible studies. This result demonstrated that the systematic review is propitious for the production and application of clinical evidence. As the participants in the meta-analysis were mostly from Asia, these findings may be more generally applicable to Asian patients. Therefore, to obtain a better understanding of the precise prognostic significance of β-catenin mutation, additional, large prospective studies with similar methods to those presented should be conducted.

Although the association between β-catenin mutation and patient prognosis in HCC was comprehensively evaluated, limitations exist in the present meta-analysis. First, the number of eligible studies included in the study was limited. Second, no unpublished studies were found. There was a possibility of publication bias, although the funnel plot showed no significant bias. Third, studies in languages other than English were excluded. The risk of language bias should be considered, but it may not lead to significant bias in the assessment of interventional effectiveness.

In conclusion, the present study indicated that the β-catenin mutation is correlated with a favorable prognosis and specific clinicopathological features in patients with HCC. As there is a paucity of evidence to clearly explain this finding, more scientific research is required to investigate the prognostic importance of β-catenin mutation among HCC patients, which may inform the choice of new adjunctive therapy for HCC cases.

 References FornerALlovetJMBruixJHepatocellular carcinomaLancet37912451255201210.1016/S0140-6736(11)61347-022353262 MaluccioMCoveyARecent progress in understanding, diagnosing and treating hepatocellular carcinomaCA Cancer J Clin62394399201210.3322/caac.2116123070690 JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.2010721296855 YangJDRobertsLRHepatocellular carcinoma: A global viewNat Rev Gastroenterol Hepatol7448458201010.1038/nrgastro.2010.10020628345 MingLThorgeirssonSSGailMHDominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, ChinaHepatology3612141220200210.1053/jhep.2002.3636612395332 MarreroJAFontanaRJFuSConjeevaramHSSuGLLokASAlcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinomaJ Hepatol42218224200510.1016/j.jhep.2004.10.00515664247 El-SeragHBHepatocellular carcinomaN Engl J Med36511181127201110.1056/NEJMra100168321992124 FaraziPADePinhoRAHepatocellular carcinoma pathogenesis: from genes to environmentNat Rev Cancer6674687200610.1038/nrc193416929323 GarrawayLALanderESLessons from the cancer genomeCell1531737201310.1016/j.cell.2013.03.00223540688 AnastasJNMoonRTWNT signalling pathways as therapeutic targets in cancerNat Rev Cancer131126201310.1038/nrc341923258168 VillanuevaANewellPChiangDYFriedmanSLLlovetJMGenomics and signaling pathways in hepatocellular carcinomaSemin Liver Dis275576200710.1055/s-2006-96017117295177 GrigoryanTWendPKlausABirchmeierWDeciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in miceGenes Dev2223082341200810.1101/gad.168620818765787 MiyoshiYIwaoKNagasawaYActivation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3Cancer Res582524252719989635572 TaniguchiKRobertsLRAdercaINMutational spectrum of beta-catenin, AXIN1 and AXIN2 in hepatocellular carcinomas and hepatoblastomasOncogene2148634871200210.1038/sj.onc.120559112101426 ElmileikHPatersonACKewMCBeta-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation and hepatitis B virus infection in southern African Blacks with hepatocellular carcinomaJ Surg Oncol91258263200510.1002/jso.2030416121349 Laurent-PuigPZucman-RossiJGenetics of hepatocellular tumorsOncogene2537783786200610.1038/sj.onc.120954716799619 FujimotoATotokiYAbeTWhole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulatorsNat Genet44760764201210.1038/ng.229122634756 KanZZhengHLiuXWhole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Res2314221433201310.1101/gr.154492.11323788652 HaradaNOshimaHKatohMTamaiYOshimaMTaketoMMHepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutationsCancer Res644854200410.1158/0008-5472.CAN-03-212314729607 TwardADJonesKDYantSDistinct pathways of genomic progression to benign and malignant tumors of the liverProc Natl Acad Sci USA1041477114776200710.1073/pnas.070657810417785413 Laurent-PuigPLegoixPBluteauOGenetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesisGastroenterology12017631773200110.1053/gast.2001.2479811375957 HoshidaYNijmanSMKobayashiMIntegrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinomaCancer Res6973857392200910.1158/0008-5472.CAN-09-108919723656 StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol25603605201010.1007/s10654-010-9491-z20652370 GoughNRFocus issue: Wnt and beta-catenin signaling in development and diseaseSci Signal5eg2201210.1126/scisignal.200280622234609 HsuHCJengYMMaoTLChuJSLaiPLPengSYBeta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosisAm J Pathol157763770200010.1016/S0002-9440(10)64590-710980116 YuanRHJengYMHuRHRole of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinomaJ Gastrointest Surg15321329201110.1007/s11605-010-1373-x21061181 MaoTLChuJSJengYMLaiPLHsuHCExpression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread and good prognosisJ Pathol19395101200110.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-311169521 HanZGFunctional genomic studies: Insights into the pathogenesis of liver cancerAnnu Rev Genomics Hum Genet13171205201210.1146/annurev-genom-090711-16375222703171 SamowitzWSPowersMDSpirioLNNolletFvan RoyFSlatteryMLBeta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomasCancer Res5914421444199910197610 GamalloCPalaciosJMorenoGCalvoDMJSuarezAArmasABeta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta-catenin gene mutations, clinicopathological features and clinical outcomeAm J Pathol155527536199910.1016/S0002-9440(10)65148-610433945 SekineSLanBYBedolliMFengSHebrokMLiver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in miceHepatology43817825200610.1002/hep.2113116557553 SekineSGutierrezPJLanBYFengSHebrokMLiver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomyHepatology45361368200710.1002/hep.2152317256747 ApteUZengGMullerPActivation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in miceHepatology449921002200610.1002/hep.2131717006939 HaradaNMiyoshiHMuraiNLack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-cateninCancer Res6219711977200211929813 GuichardCAmaddeoGImbeaudSIntegrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinomaNat Genet44694698201210.1038/ng.225622561517 LiMZhaoHZhangXInactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinomaNat Genet43828829201110.1038/ng.90321822264

Flowchart of the selection process for the meta-analysis.

Forest plots. The results of the meta-analysis for (A) 5-year overall survival; (B) hepatitis B virus infection; (C) tumor differentiation; and (D) tumor-node-metastasis stage. CI, confidence interval.

Funnel plot for the assessment of publication bias. SE, standard error; OR, odds ratio.

Characteristics of the studies included in the meta-analysis.

First author Year Patients Comparison β-catenin mutation detection Mutation, % Outcome measures Quality scorea (Refs.)
Hsu 2000 366 Wild-type DNA-sequencing 12.8 5-year OS 7 stars (25)
Mao 2001 66 Wild-type DNA-sequencing 45.4 5-year OS 6 stars (27)
Yuan 2011 186 Wild-type DNA-sequencing 14.5 5-year OS 7 stars (26)

Quality of studies was assessed according to the ‘Newcastle-Ottawa Scale for assessing the quality of non-randomized studies in meta-analyses’ standard, and the number of stars was assigned.